Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | XL147 | 3 | 72 | 0.1 | 3099.8 | 3159.8 | 1180.5 | -1.0 | 0.973 | 0.981 | 1.420 | HCC38 XL147 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.1 | 2306.5 | 3158.8 | 1180.5 | -1.0 | 0.603 | 0.730 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.001 | 2383.0 | 3158.8 | 1180.5 | -3.0 | 0.640 | 0.754 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | XL147 | 3 | 72 | 0.032 | 3143.5 | 3159.8 | 1180.5 | -1.49 | 0.993 | 0.995 | 1.420 | HCC38 XL147 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.032 | 2332.3 | 3158.8 | 1180.5 | -1.49 | 0.615 | 0.738 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.0032 | 2352.3 | 3158.8 | 1180.5 | -2.49 | 0.625 | 0.745 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | XL147 | 3 | 72 | 0.001 | 3159.8 | 3159.8 | 1180.5 | -3.0 | 1.000 | 1.000 | 1.420 | HCC38 XL147 0 3 72 |
| HCC70 | Trametinib | 1 | 72 | 0.032 | 2250.5 | 3427.3 | 1279.8 | -1.49 | 0.488 | 0.657 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.01 | 2320.3 | 3427.3 | 1279.8 | -2.0 | 0.520 | 0.677 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.0032 | 2779.5 | 3427.3 | 1279.8 | -2.49 | 0.726 | 0.811 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.001 | 3041.3 | 3427.3 | 1279.8 | -3.0 | 0.839 | 0.887 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 1.0 | 1938.3 | 3427.3 | 1279.8 | 0.0 | 0.339 | 0.566 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.32 | 1968.0 | 3427.3 | 1279.8 | -0.495 | 0.354 | 0.574 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 3.2 | 2009.0 | 3427.3 | 1279.8 | 0.505 | 0.373 | 0.586 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.1 | 1891.0 | 3427.3 | 1279.8 | -1.0 | 0.316 | 0.552 | 1.421 | HCC70 Trametinib 0 1 72 |
| HCC38 | Buparlisib | 3 | 72 | 3.2 | 599.0 | 3184.0 | 1180.5 | 0.505 | -0.377 | 0.188 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.1 | 2993.5 | 3184.0 | 1180.5 | -1.0 | 0.916 | 0.940 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.032 | 3081.0 | 3184.0 | 1180.5 | -1.49 | 0.955 | 0.968 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.32 | 2696.8 | 3184.0 | 1180.5 | -0.495 | 0.781 | 0.847 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.001 | 3052.5 | 3184.0 | 1180.5 | -3.0 | 0.942 | 0.959 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.0032 | 3075.0 | 3184.0 | 1180.5 | -2.49 | 0.952 | 0.966 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 0.01 | 2986.3 | 3184.0 | 1180.5 | -2.0 | 0.912 | 0.938 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC38 | Buparlisib | 3 | 72 | 1.0 | 1719.3 | 3184.0 | 1180.5 | 0.0 | 0.300 | 0.540 | 1.431 | HCC38 BKM120 0 3 72 |
| HCC70 | BX-912 | 1 | 72 | 1.0 | 2480.5 | 3461.8 | 1279.8 | 0.0 | 0.586 | 0.717 | 1.436 | HCC70 BX912 0 1 72 |
| HCC70 | BX-912 | 1 | 72 | 0.032 | 3679.5 | 3461.8 | 1279.8 | -1.49 | 1.090 | 1.060 | 1.436 | HCC70 BX912 0 1 72 |